stockrow
Friday 6 November 2026
Export ERAS’s income statement to Excel — free account
Erasca, Inc.
ERAS Healthcare Biotechnology
- EPS
- −16.7%
- Free cash flow
- −4.67%
Quarter to June 2026, against a year earlier
14.34
1.07
+8.06%
Follow ERAS
Alert me
Erasca, Inc. (ERAS) Book value per share
Erasca, Inc.'s book value per share at the end of fiscal 2025 was 1.1×, down 36.7% from 1.8× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 1.2×. Over the past ten years it has ranged from −5.4× (fiscal 2020) to 6.9× (fiscal 2021); the current reading is higher than 43% of that period. Erasca, Inc. ranks 332nd of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 1.1× | (36.68%) |
| FY2024 | 1.8× | (14.10%) |
| FY2023 | 2.1× | (37.53%) |
| FY2022 | 3.4× | (50.99%) |
| FY2021 | 6.9× | — |
| FY2020 | −5.4× | — |
| FY2019 | 0.4× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 1.2× | (10.12%) |
| Mar 2026 | 1.3× | 12.76% |
| Dec 2025 | 1.1× | (6.47%) |
| Sep 2025 | 1.2× | (6.65%) |
| 22 more quarters | Free account |
Against its own ten years
Low −5.4×
High 6.9×
Ten-year median
1.8×
Current reading's percentile
43
Book value per share against peers
| Company | Book value per share |
|---|---|
| DNTH Dianthus Therapeutics, Inc. compare | 21.6× |
| MANE Veradermics Incorporated compare | 20.1× |
| CRSP CRISPR Therapeutics AG compare | 17.0× |
| EWTX Edgewise Therapeutics, Inc. compare | 15.0× |
| DFTX Definium Therapeutics, Inc. compare | 8.3× |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 6.6× |
| COGT Cogent Biosciences, Inc. compare | 3.1× |
| ERAS Erasca, Inc. | 1.2× |
| TVTX Travere Therapeutics, Inc. compare | 0.2× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))